Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

CureVac Launches Specialized Phase 3 Clinical Trial of Coronavirus Vaccine Candidate

By Eric Volkman - Dec 21, 2020 at 6:49PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company's mRNA-based vaccine will be tested on healthcare workers.

A coronavirus vaccine candidate similar to that of recently approved ones from Pfizer ( PFE 1.77% ) and BioNTech ( BNTX -4.91% ) and Moderna ( MRNA -11.85% ) has now moved into late-stage testing on healthcare workers.

CureVac ( CVAC -9.54% ), like BioNTech a clinical-stage biotech based in Europe, announced Monday that its CvnCoV is about to enter phase 3 clinical trials, in testing that involves healthcare workers. The first participant in the study is to be administered the initial shot of the vaccine candidate on Tuesday.

A syringe being filled with a vaccine from a vial.

Image source: Getty Images.

This crucial phase of testing will take place at the University Medical Center Mainz in Germany. It's a randomized, placebo-controlled study with over 2,500 individuals aged 18 and older. CureVac said it compliments the company's phase 2b/3 trial, which involved more than 35,000 people and began last week.

As with Pfizer/BioNTech's and Moderna's vaccines -- both of which are in the initial phases of large-scale rollouts in the U.S. -- CureVac's essentially uses messenger RNA to "instruct" the body's cells how to defend against the coronavirus. CvnCoV was shown to be efficacious in early-stage testing, with no participant developing serious side effects.

CureVac explained the rationale behind this new, specialized testing. "With this clinical study in healthcare workers, we aim to investigate the difference our vaccine candidate can make in this specific group of individuals who are at particularly high risk of potential infection due to viral exposure," the company quoted its head of infectious diseases, Lidia Oostvogels, as saying.

Investors are clearly pleased with the progress CureVac is making with CvnCoV. They traded the stock up by 6.7% on Monday, while the S&P 500 index sank on the day.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

CureVac N.V. Stock Quote
CureVac N.V.
$43.62 (-9.54%) $-4.60
Pfizer Inc. Stock Quote
Pfizer Inc.
$54.68 (1.77%) $0.95
Moderna, Inc. Stock Quote
Moderna, Inc.
$310.68 (-11.85%) $-41.75
BioNTech SE Stock Quote
BioNTech SE
$334.48 (-4.91%) $-17.26

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/01/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.